Summary
Regeneron Pharmaceuticals, Inc. (REGN) has announced a significant move to address its outstanding convertible senior subordinated notes. On May 28th and 29th, 2008, the company repurchased $50 million of its 5.5% Convertible Senior Subordinated Notes due October 17, 2008. This action was completed in privately negotiated transactions at a slight premium to par value, indicating a proactive approach to debt management. Furthermore, Regeneron's Board of Directors has authorized the repurchase of up to an additional $150 million of these notes. This expanded authorization signals management's continued intention to reduce its convertible debt obligations. The actual execution of further repurchases will be contingent on favorable pricing, market conditions, and other factors, providing flexibility while demonstrating a commitment to optimizing the company's capital structure.
Key Highlights
- 1Regeneron repurchased $50 million in principal of its 5.5% Convertible Senior Subordinated Notes due October 17, 2008.
- 2The repurchases occurred on May 28th and 29th, 2008, in privately negotiated transactions.
- 3The notes were repurchased at 101% of par value plus accrued interest.
- 4The Board of Directors has authorized the repurchase of up to an additional $150 million of the outstanding notes.
- 5This expanded authorization allows for further debt reduction through future privately negotiated transactions.
- 6The decision to repurchase additional notes will depend on market conditions and available pricing terms.